Navigation Links
TPI Provides Updates on the Renewal Application for High Tech Enterprise Status

CHENGDU, China, Sept. 19, 2011, /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today provides the progress updates for its operating subsidiary, Chengdu Tianyin Pharmaceutical Co., Ltd's ("Chengdu Tianyin") application for the renewal of its High Tech Enterprise Status in Chengdu, Sichuan Province of China.

Chengdu Tianyin is a wholly foreign-owned enterprise incorporated in the People's Republic of China (PRC) and subject to PRC Foreign Enterprise Income Tax ("FEIT") Law. Chengdu Tianyin has been entitled to the preferential tax treatment for opening up its production facility in Western China in Sichuan Province. The applicable reduced preferential state enterprise income tax rate under this policy was 15% until December 31, 2010. Following the preferential tax treatment period, Chengdu Tianyin is currently subject to 25% income taxes.

After an initial preparation period, TPI'S High Tech Enterprise status application has been submitted to the Bureau of Science and Technology of Chengdu, Sichuan Province in June 2011. After preliminary review, additional application material has been subsequently provided for the second round of review. This includes eight technology patents and one industrial application patent. The management will provide further updates the outcome of review process.

The successful renewal of the High Tech Enterprise Status will reduce the current enterprise income tax to 15% for another three years from the beginning of 2012 calendar year.

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please visit:, or email ir@tianyinpharma.comJames Jiayuan Tong M.D. Ph.D.Tel: +86-28-8551-6696 (Chengdu, China)+86-134-3655-0011 (China)Address: Tianyin Pharmaceutical23rd Floor, Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Innocoll Provides an Update on its Range of Advanced Wound Care and Related Collagen-based Products
2. TPI Provides Updates on Jiangchuan Macrolide Facility
3. VIVUS Provides Regulatory Update on QNEXA
4. Experis Recognizes National Healthcare IT Week, Provides Tips for ICD-10 Assessment Decision
5. Questcor Provides Updated New Paid Prescription Trends
6. ADVENTRX Provides Update on All Three Pipeline Products
7. Cardium Provides Update on Exchange Listing and Related Business Matters
8. MGT Capital Investments, Inc. Provides Update on Recent Developments
9. Verathon® Introduces the Heartscape™ 3D ECG System with 80-Lead Vest in Europe; Technology Provides More Complete Data to Help Diagnose Acute Myocardial Infarction (MI)
10. Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program
11. InspireMD Provides Mid-Year Strategic Update
Post Your Comments:
(Date:11/26/2015)... , Países Bajos, November 26, 2015 ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Un nuevo enfoque combina la inmunoterapia con la terapia ... Clinical Cancer Research . --> ...
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/27/2015)... Chicago, IL (PRWEB) , ... November 27, 2015 ... ... some of the largest, most successful and prominent nonprofit healthcare organizations in the ... and governance involvement with various organizations, and helped advance the healthcare industry as ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... Avid collector, ... Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most famous ... Canterbury House at the University of Michigan in Ann Arbor. The According to Hawley, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
Breaking Medicine News(10 mins):